 |
197 Diseases |  |
398 Trials |
|
398 Trials |  |
21826 News |  |
| «12...255256257258259260261262263264265266267» |
- | Yervoy (ipilimumab) / BMS
Trial initiation date, Metastases: Study to Compare the Effect of Ipilimumab Retreatment With That of Chemotherapy in Advanced Melanoma (clinicaltrials.gov) - May 6, 2014
P2, N=23, Recruiting, Sponsor: Bristol-Myers Squibb
Initiation date: Mar 2013 --> Jan 2013
- | Yervoy (ipilimumab) / BMS
Trial initiation date, Metastases: Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage lV Malignant Melanoma (clinicaltrials.gov) - May 6, 2014
P2, N=30, Recruiting, Sponsor: Bristol-Myers Squibb
Initiation date: Mar 2013 --> Jan 2013 Initiation date: Apr 2013 --> Nov 2012
- | Yervoy (ipilimumab) / BMS
Trial initiation date, Metastases: Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma (clinicaltrials.gov) - May 6, 2014
P2, N=45, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Initiation date: Apr 2013 --> Nov 2012 Initiation date: Oct 2012 --> Sep 2012
- || Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Trial initiation date, PD(L)-1 Biomarker, IO biomarker: CheckMate 040: An Immuno-therapy Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab or Nivolumab in Combination With Other Agents in Patients With Advanced Liver Cancer (clinicaltrials.gov) - May 6, 2014
P1, N=90, Recruiting, Sponsor: Bristol-Myers Squibb
Initiation date: Oct 2012 --> Sep 2012 Initiation date: Oct 2012 --> Sep 2012
- ||||| Yervoy (ipilimumab) / Ono Pharma, BMS
Trial initiation date: Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy Alone (clinicaltrials.gov) - May 6, 2014
P3, N=1100, Recruiting, Sponsor: Bristol-Myers Squibb
Initiation date: Oct 2012 --> Sep 2012 Initiation date: Jan 2012 --> Dec 2011
- ||||| Yervoy (ipilimumab) / Ono Pharma, BMS
Trial initiation date: Efficacy Study of Ipilimumab Versus Placebo to Prevent Recurrence After Complete Resection of High Risk Stage III Melanoma (clinicaltrials.gov) - May 6, 2014
P3, N=950, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Initiation date: Jan 2012 --> Dec 2011 Initiation date: Jun 2008 --> May 2008
- Yervoy (ipilimumab) / BMS
Trial completion date, Metastases: Phase 2 Study of Ipilimumab in Japanese Advanced Melanoma Patients (clinicaltrials.gov) - May 6, 2014
P2, N=18, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Initiation date: Jun 2008 --> May 2008 Trial completion date: Mar 2015 --> Feb 2015
- Yervoy (ipilimumab) / BMS
Trial completion date, Metastases: Study to Compare the Effect of Ipilimumab Retreatment With That of Chemotherapy in Advanced Melanoma (clinicaltrials.gov) - May 6, 2014
P2, N=23, Recruiting, Sponsor: Bristol-Myers Squibb
Trial completion date: Mar 2015 --> Feb 2015 Trial completion date: Jul 2016 --> Jul 2014
- Yervoy (ipilimumab) / BMS
Trial completion date, Metastases: Phase 2 Study of Ipilimumab Plus Dacarbazine in Japanese Patients With Advanced Melanoma (clinicaltrials.gov) - May 6, 2014
P2, N=26, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Trial completion date: Jul 2016 --> Jul 2014 Trial completion date: Jan 2015 --> Aug 2014
- | Yervoy (ipilimumab) / BMS
Enrollment open, Metastases: Study to Compare the Effect of Ipilimumab Retreatment With That of Chemotherapy in Advanced Melanoma (clinicaltrials.gov) - May 6, 2014
P2, N=23, Recruiting, Sponsor: Bristol-Myers Squibb
Trial completion date: Jan 2015 --> Aug 2014 Active, not recruiting --> Recruiting
- || lirilumab (BMS-986015) / Innate, BMS, Ono Pharma, Yervoy (ipilimumab) / BMS
Trial primary completion date, Combination therapy, Metastases: Safety Study of BMS-986015 (Anti-KIR) in Combination With Ipilimumab in Subjects With Selected Advanced Tumor (clinicaltrials.gov) - May 6, 2014
P1, N=125, Recruiting, Sponsor: Bristol-Myers Squibb
Active, not recruiting --> Recruiting Trial primary completion date: Jul 2015 --> Oct 2016
- |||| Yervoy (ipilimumab) / BMS
Trial primary completion date, Metastases: Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer (clinicaltrials.gov) - May 6, 2014
P3, N=600, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Trial primary completion date: Jul 2015 --> Oct 2016 Trial primary completion date: Jan 2015 --> Nov 2015
- | lirilumab (BMS-986015) / Innate, BMS, Ono Pharma, Yervoy (ipilimumab) / BMS
Trial completion date, Combination therapy, Metastases: Safety Study of BMS-986015 (Anti-KIR) in Combination With Ipilimumab in Subjects With Selected Advanced Tumor (clinicaltrials.gov) - May 6, 2014
P1, N=125, Recruiting, Sponsor: Bristol-Myers Squibb
Trial primary completion date: Jan 2015 --> Nov 2015 Trial completion date: Jul 2015 --> Oct 2016
- | lirilumab (BMS-986015) / Innate, BMS, Ono Pharma, Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Combination therapy, Metastases: A Study of an Anti-KIR Antibody Lirilumab in Combination With an Anti-PD1 Antibody Nivolumab and Nivolumab Plus an Anti-CTLA-4 Ipilimumab Antibody in Patients With Advanced Solid Tumors (clinicaltrials.gov) - May 6, 2014
P1, N=162, Recruiting, Sponsor: Bristol-Myers Squibb
Trial completion date: Jul 2015 --> Oct 2016 Trial completion date: Sep 2015 --> Jan 2017
- ||| Yervoy (ipilimumab) / BMS
Trial completion date, Metastases: Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer (clinicaltrials.gov) - May 6, 2014
P3, N=600, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Trial completion date: Sep 2015 --> Jan 2017 Trial completion date: Nov 2015 --> Feb 2016
- | Yervoy (ipilimumab) / BMS
Enrollment closed, Metastases: Phase 2 Study of Ipilimumab in Japanese Advanced Melanoma Patients (clinicaltrials.gov) - May 6, 2014
P2, N=18, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Trial completion date: Nov 2015 --> Feb 2016 Recruiting --> Active, not recruiting
- | Yervoy (ipilimumab) / BMS
Enrollment closed, Metastases: Phase 2 Study of Ipilimumab Plus Dacarbazine in Japanese Patients With Advanced Melanoma (clinicaltrials.gov) - May 6, 2014
P2, N=26, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- ||||| Yervoy (ipilimumab) / BMS
Trial initiation date, Metastases: Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer (clinicaltrials.gov) - May 6, 2014
P3, N=600, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Recruiting --> Active, not recruiting Initiation date: Jun 2001 --> Jul 2010
- ||| Yervoy (ipilimumab) / BMS
Enrollment change, Metastases: Study to Compare the Effect of Ipilimumab Retreatment With That of Chemotherapy in Advanced Melanoma (clinicaltrials.gov) - May 6, 2014
P2, N=138, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Initiation date: Jun 2001 --> Jul 2010 N=180 --> 138
- | Yervoy (ipilimumab) / BMS
Trial initiation date, Monotherapy: Phase II Study of Ipilimumab Monotherapy in Recurrent Platinum-sensitive Ovarian Cancer (clinicaltrials.gov) - May 5, 2014
P2, N=40, Recruiting, Sponsor: Bristol-Myers Squibb
N=180 --> 138 Initiation date: Aug 2012 --> Nov 2012
- | Zelboraf (vemurafenib) / Roche, Yervoy (ipilimumab) / BMS
Trial termination, Combination therapy, Metastases: Study for the Evaluation of Vemurafenib ( Zelboraf (clinicaltrials.gov) - May 4, 2014
P1/2, N=95, Terminated, Sponsor: Cancer Centre of Monoclonal Therapy, LLC
Enrolling by invitation --> Terminated; When used appear DNE3 toxic properties. The DSMB determined that due to higher than expected risk and safety concerns the study should be closed.
- Tarvacin (bavituximab) / OncXerna Therap, Yervoy (ipilimumab) / BMS
Enrollment open, Metastases: A Two-arm, Single Center Phase 1b Trial of Bavituximab Plus Ipilimumab in Advanced Melanoma Patients (clinicaltrials.gov) - May 4, 2014
P1, N=24, Recruiting, Sponsor: University of Texas Southwestern Medical Center
The DSMB determined that due to higher than expected risk and safety concerns the study should be closed. Not yet recruiting --> Recruiting
- Yervoy (ipilimumab) / BMS
Trial initiation date, Metastases: Phase II Trial of Stereotactic Body Radiotherapy Followed by Ipilimumab in Treating Patients With Stage IV Melanoma (clinicaltrials.gov) - May 1, 2014
P1/2, N=40, Recruiting, Sponsor: University of Washington
Not yet recruiting --> Recruiting Initiation date: Oct 2013 --> Feb 2014
- || Yervoy (ipilimumab) / BMS
Trial completion date, Monotherapy: A Companion Study for Patients Enrolled in Prior/Parent Ipilimumab Studies (clinicaltrials.gov) - Apr 24, 2014
P2, N=248, Completed, Sponsor: Bristol-Myers Squibb
Initiation date: Oct 2013 --> Feb 2014 Trial completion date: Sep 2014 --> Apr 2014
- |||| Yervoy (ipilimumab) / BMS
Trial completion, Monotherapy: A Companion Study for Patients Enrolled in Prior/Parent Ipilimumab Studies (clinicaltrials.gov) - Apr 24, 2014
P2, N=248, Completed, Sponsor: Bristol-Myers Squibb
Trial completion date: Sep 2014 --> Apr 2014 Active, not recruiting --> Completed
- Yervoy (ipilimumab) / BMS
Trial completion: Phase I Study of Ipilimumab (Anti-CTLA-4) in Children and Adolescents With Treatment-Resistant Cancer (clinicaltrials.gov) - Apr 18, 2014
P1, N=28, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Recruiting --> Completed
- | Yervoy (ipilimumab) / BMS
Enrollment change, Metastases: Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage lV Malignant Melanoma (clinicaltrials.gov) - Apr 17, 2014
P2, N=40, Ongoing, Sponsor: Bristol-Myers Squibb International Corporation
Recruiting --> Completed N=30 --> 40
- ||||| Yervoy (ipilimumab) / Ono Pharma, BMS
Trial initiation date, Metastases: Phase 3 Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Versus Placebo in Addition to Paclitaxel and Carboplatin (clinicaltrials.gov) - Apr 15, 2014
P3, N=920, Recruiting, Sponsor: Bristol-Myers Squibb
N=30 --> 40 Initiation date: Aug 2011 --> Jan 2011
- belapectin (GR-MD-02) / Galectin Therap, Yervoy (ipilimumab) / Ono Pharma, BMS
New P1 trial, Metastases: Galectin Inhibitor (GR-MD-02) and Ipilimumab in Patients With Metastatic Melanoma (clinicaltrials.gov) - Apr 15, 2014
P1, N=22, Recruiting, Sponsor: Providence Health & Services
- ||| Yervoy (ipilimumab) / BMS
Trial initiation date: GRAY-B: GEM STUDY: Radiation And Yervoy in Patients With Melanoma and Brain Metastases (clinicaltrials.gov) - Apr 14, 2014
P2, N=66, Recruiting, Sponsor: Grupo Espa
Initiation date: Aug 2011 --> Jan 2011 Initiation date: May 2014 --> Apr 2014
- |||| Yervoy (ipilimumab) / BMS
Enrollment open: GRAY-B: GEM STUDY: Radiation And Yervoy in Patients With Melanoma and Brain Metastases (clinicaltrials.gov) - Apr 14, 2014
P2, N=66, Recruiting, Sponsor: Grupo Espa
Initiation date: May 2014 --> Apr 2014 Not yet recruiting --> Recruiting
- Yervoy (ipilimumab) / BMS
Trial termination, Metastases: Safety and Efficacy Trial of Ipilimumab Versus Pemetrexed in Non-Squamous Non-Small Cell Lung Cancer (clinicaltrials.gov) - Apr 13, 2014
P2, N=9, Terminated, Sponsor: Bristol-Myers Squibb
Not yet recruiting --> Recruiting Completed --> Terminated; Administrative reasons
- ||||| Yervoy (ipilimumab) / BMS
New P2 trial: GRAY-B: GEM STUDY: Radiation And Yervoy in Patients With Melanoma and Brain Metastases (clinicaltrials.gov) - Apr 13, 2014
P2, N=66, Recruiting, Sponsor: Grupo Espa
- Yervoy (ipilimumab) / Ono Pharma, BMS
New P1/2 trial: Trial of Neoadjuvant Ipilimumab Followed by Melphalan Via Isolated Limb Infusion for Patients With Unresectable In-transit Extremity Melanoma (clinicaltrials.gov) - Apr 13, 2014
P1/2, N=44, Not yet recruiting, Sponsor: Douglas Tyler
- | Yervoy (ipilimumab) / BMS
New P2 trial, Tumor-specific neoantigens, Metastases: T-Cell Responses to Neoantigens Post Treatment With Ipilimumab in Men With Metastatic Castration-Resistant Prostate Cancer (clinicaltrials.gov) - Apr 10, 2014
P2, N=20, Not yet recruiting, Sponsor: M.D. Anderson Cancer Center
- || Opdivo (nivolumab) / BMS
Monotherapy, PD(L)-1 Biomarker, IO biomarker: CheckMate 039: An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma (clinicaltrials.gov) - Apr 7, 2014
P1, N=180, Recruiting, Sponsor: Bristol-Myers Squibb
Completed --> Terminated; Administrative reasons N=110 --> 180
- | Yervoy (ipilimumab) / BMS
New P2 trial, Metastases: Stereotactic Radiation Therapy and Ipilimumab in Treating Patients With Metastatic Melanoma (clinicaltrials.gov) - Apr 6, 2014
P2, N=32, Not yet recruiting, Sponsor: Ohio State University Comprehensive Cancer Center
- Xalkori (crizotinib) / Pfizer
Enrollment open, Checkpoint inhibition, PD(L)-1 Biomarker, IO biomarker: Combination Checkpoint Inhibitor Plus Erlotinib or Crizotinib for EGFR or ALK Mutated Stage IV Non-small Cell Lung Cancer (clinicaltrials.gov) - Apr 6, 2014
P1, N=46, Recruiting, Sponsor: University of Utah
N=110 --> 180 Not yet recruiting --> Recruiting
- Surgery, Metastases: Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery (clinicaltrials.gov) - Apr 6, 2014
P2, N=168, Recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- |||| Keytruda (pembrolizumab) / Merck (MSD)
Metastases: KEYNOTE 029: Safety and Tolerability of Pembrolizumab (MK-3475) + Pegylated Interferon Alfa-2b and Pembrolizumab+ Ipilimumab in Participants With Advanced Melanoma or Renal Cell Carcinoma (MK-3475-029/KEYNOTE-29) (clinicaltrials.gov) - Apr 1, 2014
P1/2, N=195, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- || Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Enrollment closed: Dose-escalation Study of Combination BMS-936558 (MDX-1106) and Ipilimumab in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma (clinicaltrials.gov) - Apr 1, 2014
P1, N=136, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- |||| Enrollment open, Checkpoint inhibition: NLG-0304: Immunotherapy Study for Patients With Stage IV Melanoma (clinicaltrials.gov) - Mar 31, 2014
P2b, N=100, Recruiting, Sponsor: NewLink Genetics Corporation
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- ||||| Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Enrollment closed, Monotherapy, PD(L)-1 Biomarker, IO biomarker: Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067) (clinicaltrials.gov) - Mar 31, 2014
P3, N=915, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- Yervoy (ipilimumab) / Ono Pharma, BMS
Trial withdrawal, Metastases: Study of the Combination of Anti-OX40 and Ipilimumab in Patients With Metastatic Melanoma (clinicaltrials.gov) - Mar 30, 2014
P1/2, N=0, Withdrawn, Sponsor: Ludwig Institute for Cancer Research
Recruiting --> Active, not recruiting Suspended --> Withdrawn
- Yervoy (ipilimumab) / Ono Pharma, BMS
Trial initiation date, Metastases: Study of the Combination of Anti-OX40 and Ipilimumab in Patients With Metastatic Melanoma (clinicaltrials.gov) - Mar 30, 2014
P1/2, N=0, Withdrawn, Sponsor: Ludwig Institute for Cancer Research
Suspended --> Withdrawn Initiation date: Oct 2012 --> Mar 2014
- Yervoy (ipilimumab) / Ono Pharma, BMS
Enrollment change, Metastases: Study of the Combination of Anti-OX40 and Ipilimumab in Patients With Metastatic Melanoma (clinicaltrials.gov) - Mar 30, 2014
P1/2, N=0, Withdrawn, Sponsor: Ludwig Institute for Cancer Research
Initiation date: Oct 2012 --> Mar 2014 N=60 --> 0
- Yervoy (ipilimumab) / BMS
Enrollment open, Metastases: Phase II Trial of Stereotactic Body Radiotherapy Followed by Ipilimumab in Treating Patients With Stage IV Melanoma (clinicaltrials.gov) - Mar 26, 2014
P1/2, N=40, Recruiting, Sponsor: University of Washington
N=60 --> 0 Not yet recruiting --> Recruiting
- Yervoy (ipilimumab) / BMS
New P2 trial, Surgery: Ipilimumab Induction in Patients With Melanoma Brain Metastases Receiving Stereotactic Radiosurgery (clinicaltrials.gov) - Mar 25, 2014
P2, N=40, Not yet recruiting, Sponsor: Christopher Lao
- ||||| Zelboraf (vemurafenib) / Roche, Yervoy (ipilimumab) / BMS
New P1/2 trial, Combination therapy, Metastases: Study for the Evaluation of Vemurafenib ( Zelboraf (clinicaltrials.gov) - Mar 24, 2014
P1/2, N=95, Enrolling by invitation, Sponsor: Cancer Centre of Monoclonal Therapy, LLC
- |||| Opdivo (nivolumab) / BMS
Enrollment open, MSi-H Biomarker, PD(L)-1 Biomarker: CheckMate 142: A Study of Nivolumab Alone or Nivolumab Combination Therapy in Colon Cancer That Has Come Back or Has Spread (clinicaltrials.gov) - Mar 24, 2014
P1/2, N=96, Recruiting, Sponsor: Bristol-Myers Squibb
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting